Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157117 | 1.00 | VDR (0.73) | VDRAR | |
| SCHEMBL5153777 | 0.91 | VDR (0.78) | VDRAR | |
| SCHEMBL1052998 | 0.91 | VDR (0.78) | VDRAR | |
| SCHEMBL5155973 | 0.90 | VDR (0.73) | VDRAR | |
| SCHEMBL5153525 | 0.88 | VDR (0.64) | VDRAR | |
| SCHEMBL5153504 | 0.88 | VDR (0.64) | VDRAR | |
| SCHEMBL5156926 | 0.86 | HDAC6 (0.57) | VDRAR | |
| SCHEMBL5159067 | 0.86 | HDAC6 (0.57) | VDRAR | |
| SCHEMBL5156913 | 0.86 | HDAC6 (0.57) | VDRAR | |
| SCHEMBL5157185 | 0.84 | VDR (0.53) | VDRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4782688-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| US-7863298-B2 | Bridged ring structures as pharmaceutical agents | EXELIXIS, INC. (US) | 2011-01-04 | — | — | US | claimed |
| EP-1675812-B1 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2010-01-20 | — | — | EP | claimed |
| US-20070225377-A1 | Bridged Ring Structures as Pharmaceutical Agents | X-CEPTOR THERAPEUTICS, INC. (US) | 2007-09-27 | — | — | US | claimed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | claimed |
| EP-1675812-A2 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2006-07-05 | — | — | EP | claimed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | claimed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | claimed |
| WO-2005037755-A2 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-7863298-B2 | Bridged ring structures as pharmaceutical agents | EXELIXIS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1675812-B1 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090163453-A1 | Prevention and Treatment of Gastrointestinal and Bladder Disorders Associated with Chemotherapy or Radiation Therapy Using Active Vitamin D Compounds | NOVACEA INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090069276-A1 | Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof | NOVACEA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1928471-A2 | PREVENTION AND TREATMENT OF GASTROINTESTINAL AND BLADDER DISORDERS ASSOCIATED WITH CHEMOTHERAPY OR RADIATION THERAPY USING ACTIVE VITAMIN D COMPOUNDS | Novacea, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20060172014-A1 | Treatment of lung cancer with active vitamin D compounds in combination with other treatments | NOVACEA, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006074226-A2 | PREVENTION OF THROMBOTIC DISORDERS WITH ACTIVE VITAMIN D COMPOUNDS OR MIMICS THEREOF | NOVACEA, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1675812-A2 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005037755-A2 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225377-A1 | Bridged Ring Structures as Pharmaceutical Agents | VDR, CYP24A1, CYP2R1 | VDR 1/4885AR 248/4885 |
| US-20060172014-A1 | Treatment of lung cancer with active vitamin D compounds in combination with other treatments | VDR, CYP24A1, CYP27B1 | VDR 1/4885AR 2768/4885 |
| US-20090163453-A1 | Prevention and Treatment of Gastrointestinal and Bladder Disorders Associated with Chemotherapy or Radiation Therapy Using Active Vitamin D Compounds | VDR, CYP24A1, CYP27B1 | VDR 1/4885AR 2440/4885 |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | VDR, CYP2R1, CYP24A1 | VDR 1/4885AR 275/4885 |
| US-20090069276-A1 | Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof | VDR, CYP24A1, CYP27B1 | VDR 1/4885AR 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.